Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer

Clinica Chimica Acta

Volumn 326, Issue 1-2, 2002, Pages 81-95

  Wians Jr , Frank H ^a   Cheli, Carol D ^b   Balko, Jody A ^a   Bruzek, Debra J ^c   Chan, Daniel W ^c   Sokoll, Lori J ^c  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b BAYER CORPORATION   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Benign prostatic hyperplasia; Equimolar response assay; Prostate cancer; Prostate specific antigen; Receiver operator characteristic curve; Skewed response assay

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EVALUATION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; AREA UNDER THE CURVE; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; REFERENCE VALUE; ROC CURVE;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; DIAGNOSIS, DIFFERENTIAL; EVALUATION STUDIES; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; ROC CURVE;

EID: 0036889583     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00250-4     Document Type: Article

References (76)

1. Barry M.J. Prostate-specific antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 344:2001;1373-1377.
2. Partin A.W., Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J. Urol. 152:1994;1358-1368.
3. Oesterling J.E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:1991;907-923.
4. Partin A.W., Pound C.R., Lemens J.Q., Epstein J.I., Walsh P.C. Serum PSA after radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. North Am. 20:1993;713-725.
5. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
6. Lange P.H., Ercole C.J., Lightner D.J., Fraley E.E., Vessella R. The value of serum prostate-specific antigen determinations before and after radical prostatectomy. J. Urol. 141:1989;873-879.
7. Jung K., Brux B., Lein M., Rudolph B., Kristiansen G.et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin. Chem. 46:2000;47-54.
8. Stephan C., Jung K., Lein M., Pranav S., Schnorr D., Loening S.A. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol. Biomark. Prev. 9:2000;1133-1147.
9. Sokoll L.J., Chan D.W. Total, free, and complexed prostate-specific antigen: analysis and clinical utility. J. Clin. Ligand Assay. 21:1998;171-179.
10. Cuny C., Pham L., Kramp W., Sharp T., Soriano T.F. Evaluation of a 2-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. Clin. Chem. 42:1996;1243-1249.
11. Zhou A.M., Prakash C.T., Bluestein B.J., Caldwell G.W., Larsen F.L. Multiple forms of prostate-specific antigen in immunorecognition by monoclonal and polyclonal assays. Clin. Chem. 39:1993;2483-2491.
12. 1-antichymotrypsin in blood. Cancer. 37:1992;1618-1625.
13. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
14. 1-antichymotrypsin. Clin. Chem. 37:1991;1618-1625.
15. 2-macroglobulin. Clin. Chem. 44:1998;2471-2479.
16. Schröder F.H., van der Cruijsen-Koeter I., de Koning H.J., Vis A.N., Hoedemaeker R.F., Kranse R. Prostate cancer detection at low prostate specific antigen. J. Urol. 163:2000;806-812.
17. Smith D.S., Carvalhal G.F., Mager D.E., Bullock A.D., Catalona W.J. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J. Urol. 160:1998;1734-1738.
18. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 277:1997;1452-1455.
19. Nadler R.B., Humphrey P.A., Smith D.S., Catalona W.J., Ratliff T.L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J. Urol. 154:1995;407-413.
20. van Duijnhoven H.L.P., Péquériaux N.C.V., Van Zon J.P.H.M., Blankenstein M.A. Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient. Clin. Chem. 42:1996;637-641.
21. Allard W.J., Zhou Z., Yeung K.K. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin. Chem. 44:1998;1216-1223.
22. Sokoloff R.L., Wolfert R.L., Rittenhouse H.G. Standardization of PSA immunoassays: proposals and practical limitations. J. Clin. Ligand Assay. 18:1995;86-92.
23. Graves H.C.B. Standardization of immunoassays for prostate-specific antigen: a problem of prostate-specific antigen complexation or a problem of assay design? Cancer. 72:1993;3141-3144.
24. Graves H.C.B. Issues on standardization of immunoassays for prostate-specific antigen: a review. Clin. Invest. Med. 16:1993;415-424.
25. Wians F.H. Jr. The "correct" PSA concentration. Clin. Chem. 42:1996;1882-1884.
26. Nagasaki H.N., Watanabe M., Komatsu N., Kaneko T., Dubé J.Y.et al. Epitope analysis of a prostate-specific antigen (PSA) C-terminal-specific monoclonal antibody and new aspects for the discrepancy between equimolar and skewed PSA assays. Clin. Chem. 45:1999;486-496.
27. Blase A.B., Sokoloff R.L., Smith K.M. Five PSA methods compared by assaying samples with defined PSA ratios. Clin. Chem. 44:1998;191-193.
28. Strobel S., Smith K., Wolfert R., Rittenhouse H. Role of free PSA in discordance across commercial PSA assays. Clin. Chem. 42:1996;645-647.
29. Junker R., Brandt B., Zechel C., Assmann G. Comparison of prostate-specific antigen (PSA) measured by 4 combinations of free PSA and total PSA assays. Clin. Chem. 43:1997;1588-1594.
30. Okegawa T., Noda H., Nutahara K., Higashihara E. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur. Urol. 38:2000;380-387.
31. Jung K., Elgeti U., Lein M., Brux B., Pranav S.et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin. Chem. 46:2000;55-62.
32. Stamey T.A., Yemoto C.E. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition z1 volume. J. Urol. 163:2000;119-126.
33. España F., Royo M., Martínez M., Enguídanos M.J., Vera C.S.et al. Free and complexed prostate specific antigen in the identification of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. J. Urol. 160:1998;2081-2088.
34. Chan D.W., Kelley C.A., Ratliff T.L., D'Agostino D., Ritchey J.et al. Analytical and clinical performance characteristics of Hybritech's Tandem-R free PSA assay during a large multicenter trial to determine the clinical utility of percentage of free prostate-specific antigen. Clin. Chem. 45:1999;1863-1865.
35. Ellis W.J., Etzioni R., Vessella R.L., Hu C., Goodman G.E. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer. J. Urol. 166:2001;93-99.
36. Mitchell I.D.C., Croal B.L., Dickie A., Cohen N.P., Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J. Urol. 165:2001;1549-1553.
37. Hoffmann R.M., Clanon D.L., Littenberg B., Frank J.J., Peirce J.C. Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J. Gen. Intern. Med. 15:2000;739-748.
38. Fox M.P., Reilly A.A., Schneider E. Effect of the ratio of free to total prostate-specific antigen on interassay variability in proficiency test samples. Clin. Chem. 45:1999;1181-1189.
39. Veltri R.W., Miller M.C. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of 2 different test populations. Urology. 53:1999;736-745.
40. Djavan B., Zlotta A.R., Remzi M., Ghawidel K., Bursa B.et al. Total and transition z1 prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology. 54:1999;846-852.
41. Yoshida K., Honda M., Sumi S., Arai K., Suzuki S., Kitahara S. Levels of free prostate-specific antigen (PSA) can be selectively measured by heat treatment of serum: free/total PSA ratios improve detection of prostate carcinoma. Clin. Chim. Acta. 280:1999;195-203.
42. Mitrunen K., Pettersson K., Piironen T., Björk T., Lilja H., Lövgren T. Dual-label 1-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentration and ratios in serum. Clin. Chem. 41:1995;1115-1120.
43. De la Taille A., Houlgatte A., Houdelette P., Goluboff E.T., Berlizot P., Ricordel I. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of 3 assays. Br. J. Urol. 82:1998;389-392.
44. Recker F., Kwiatkowski M.K., Prronen T., Petterssson K., Goepel M., Tscholl R. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. Br. J. Urol. 81:1998;532-538.
45. Bangma C.H., Rietbergen J.B.W., Kranse R., Blijenberg B.G., Petterson K., Schröder F.H. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J. Urol. 157:1997;2191-2196.
46. Roehrborn C.G., Gregory A., McConnell J.D., Sagalowsky A.I., Wians F.H. Jr. Comparison of 3 assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology. 48:1996;23-32.
47. Pearson J.D., Luderer A.A., Metter E.J., Partin A.W., Chan D.W., Fozard J.L.et al. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology. 48:1996;4-9.
48. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N.P., Gasior G.H., Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 48:1996;55-61.
49. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C.et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 279:1998;1542-1547.
50. España F., Martinez M., Royo M., Vera C.S., Estellés A.et al. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia. Eur. Urol. 32:1997;268-272.
51. España F., Martinez M., Royo M., Vera C.S., Estellés A.et al. Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment. Eur. J. Cancer. 34:1998;1375-1380.
52. Okegawa T., Kinjo M., Watanabe K., Noda H., Kato M.et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL. BJU Int. 85:2000;708-714.
53. Okihara K., Fritsche H.A., Ayala A., Johnston D.A., Allard W.J., Babaian R.J. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/mL. J. Urol. 165:2001;1930-1936.
54. Brawer M.K., Cheli C.D., Neaman I.E., Goldblatt J., Smith C.et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J. Urol. 163:2000;1476-1480.
55. Okihara K., Cheli C.D., Partin A.W., Fritsche H.A., Chan D.W.et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J. Urol. 167:2002;2017-2024.
56. Allard W.J., Cheli C.D., Morris D.L., Goldblatt J., Pierre Y.et al. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno-1™ complexed PSA assay. Int. J. Biol. Markers. 14:1999;73-83.
57. Maeda H., Arai Y., Aoki Y., Okubo K., Okada T., Maekawa S. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer. Urology. 54:1999;225-228.
58. Brawer M.K. Complexed PSA: the newest advance in PSA testing. Urology. 54:1999;2-3.
59. Rittenhouse H.G., Chan D.W. Can complexed PSA be used as a single test for detecting prostate cancer? Urology. 54:1999;4-5.
60. Filella X., Alcover J., Molina A., Corral J.M., Carretero P., Balesta A.M. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. Prostate. 42:2000;181-185.
61. Stieber W.R., Schmeller N., Nagel D., Moghadam A.F. Alpha1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate? Anticancer Res. 17:1997;4767-4770.
62. Catalona W.J. Management of cancer of the prostate. N. Engl. J. Med. 331:1994;996-1004.
63. Oesterling J.E., Moyad M.A., Wright G.L. Jr., Beck G.R. An analytical comparison of the 3 most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx. Urology. 46:1995;524-532.
64. Zhou Z., Armstrong E.G., Belenky A., Freeman J.V., Yeung K.K. Equivalent recognition of free and ACT-complexed PSA in monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody. J. Clin. Lab. Anal. 12:1998;242-249.
65. Blijenberg B.G., Storm B.N., Van Zelst B.D., Boeken Durger A.E., Schröder F.H. New developments in the standardization of total prostate-specific antigen. Clin. Biochem. 32:1999;627-634.
66. Semjonow A., Oberpenning F., Brandt B., Zechel C., Brandau W., Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology. 48:1996;10-15.
67. Semjonow A., Oberpenning F., Weining C., Schön M., Brandt B.et al. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin. Chem. 47:2001;1472-1475.
68. Stamey T.A. Second standard conference on international standardization for prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology. 45:1995;173-184.
69. Cheli C.D., Martin M., Levine J., Zhou Z., Anderson P.H., Bankson D.D.et al. Variation in the quantitation of prostate-specific antigen in reference material: differences in commercial immunoassays. Clin. Chem. 44:1998;1551-1553.
70. Paus E., Nilsson O., Børmer O.P., Fosså S.D., Otnes B., Skovlund E. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J. Urol. 159:1998;1595-1599.
71. Pettersson K., Piironen T., Seppälä M., Liukkonen L., Christensson A., Matikainen M.-T.et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-1-antichymotrypsin complex. Clin. Chem. 41:1995;1480-1488.
72. Woodrum D., French C., Shamel L.B. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology. 48(6A):1996;33-39.
73. Delgado J.C., Loughlin K.R., Bosch R.J., Tanasijevic M.J. Comparison of the Tandem-E immunoenzymetric and Immuno-1 PSA assays. Lab. Med. 33:2002;208-211.
74. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:1982;29-36.
75. Thompson M.L., Zucchini W. On the statistical analysis of ROC curves. Stat. Med. 8:1989;1277-1290.
76. McClish D.K. Analyzing a portion of the ROC curve. Med. Decis. Mak. 9:1989;190-195.